# Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

> **NCT02094872** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 49 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IIIA Melanoma
- Stage IIIB Melanoma
- Stage IIIC Melanoma
- Stage IV Melanoma

## Interventions

- **OTHER:** cytology specimen collection procedure
- **DRUG:** MEK 162 therapy or molecularly targeted therapy
- **PROCEDURE:** therapeutic procedure
- **OTHER:** laboratory biomarker analysis
- **OTHER:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT02094872
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2020-01-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02094872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02094872, "Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02094872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*